On the public citation graph
Potential Strategies for Increasing Drug-Discovery Productivity
0 signed · 105 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/anie.201208749openalex-snapshot
Target Identification for Small Bioactive Molecules: Finding the Needle in the Haystack
inferredcites →https://doi.org/10.1002/cncr.20975openalex-snapshot
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
inferredcites →https://doi.org/10.1016/j.bcp.2005.10.024openalex-snapshot
Molecular cloning and radioligand binding characterization of the chemokine receptor CCR5 from rhesus macaque and human
inferredcites →https://doi.org/10.1016/j.bmcl.2004.12.080openalex-snapshot
Discovery and SAR of new benzazepines as potent and selective 5-HT2C receptor agonists for the treatment of obesity
inferredcites →https://doi.org/10.1016/j.bmcl.2010.08.134openalex-snapshot
Second generation 2-pyridyl biphenyl amide inhibitors of the hedgehog pathway
inferredcites →https://doi.org/10.1016/j.cbpa.2010.06.166openalex-snapshot
Rational approaches to targeted polypharmacology: creating and navigating protein–ligand interaction networks
inferredcites →https://doi.org/10.1016/j.cbpa.2010.06.176openalex-snapshot
Drug–target residence time: critical information for lead optimization
inferredcites →https://doi.org/10.1016/j.drudis.2006.02.005openalex-snapshot
Strategies to optimize the validity of disease models in the drug discovery process
inferredcites →https://doi.org/10.1016/j.drudis.2006.03.015openalex-snapshot
Drug discovery: selecting the optimal approach
inferredcites →https://doi.org/10.1016/j.drudis.2007.10.017openalex-snapshot
Unfinished business: target-based drug discovery
inferredcites →https://doi.org/10.1016/j.drudis.2008.03.011openalex-snapshot
A case study of lean drug discovery: from project driven research to innovation studios and process factories
inferredcites →https://doi.org/10.1016/j.drudis.2009.03.005openalex-snapshot
Making medicinal chemistry more effective—application of Lean Sigma to improve processes, speed and quality
inferredcites →https://doi.org/10.1016/j.drudis.2010.06.008openalex-snapshot
Label-free whole-cell assays: expanding the scope of GPCR screening
inferredcites →https://doi.org/10.1016/j.drudis.2010.11.005openalex-snapshot
Creativity, innovation and lean sigma: a controversial combination?
inferredcites →https://doi.org/10.1016/j.drudis.2011.09.012openalex-snapshot
Hypothesis driven drug design: improving quality and effectiveness of the design-make-test-analyse cycle
inferredcites →https://doi.org/10.1016/j.drudis.2011.12.020openalex-snapshot
Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival
inferredcites →https://doi.org/10.1016/j.drudis.2012.01.010openalex-snapshot
Medicinal chemistry matters – a call for discipline in our discipline
inferredcites →https://doi.org/10.1016/j.drudis.2012.04.009openalex-snapshot
What is the most important approach in current drug discovery: doing the right things or doing things right?
inferredcites →https://doi.org/10.1016/j.drudis.2012.05.007openalex-snapshot
Drug discovery in pharmaceutical industry: productivity challenges and trends
inferredcites →https://doi.org/10.1016/j.drudis.2012.10.010openalex-snapshot
Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift
inferredcites →https://doi.org/10.1016/j.drudis.2013.01.008openalex-snapshot
Shifting from the single to the multitarget paradigm in drug discovery
inferredcites →https://doi.org/10.1016/j.ejphar.2010.09.019openalex-snapshot
Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit
inferredcites →https://doi.org/10.1016/j.jep.2004.04.005openalex-snapshot
A novel extract SB-300 from the stem bark latex of Croton lechleri inhibits CFTR-mediated chloride secretion in human colonic epithelial cells
inferredcites →https://doi.org/10.1016/j.sbi.2006.01.013openalex-snapshot
Can we rationally design promiscuous drugs?
inferredcites →https://doi.org/10.1016/j.tips.2008.03.005openalex-snapshot
Allosteric inhibitors of chemoattractant receptors: opportunities and pitfalls
inferredcites →https://doi.org/10.1016/s0022-3565(24)29537-9openalex-snapshot
Anti-Inflammatory and Immunomodulatory Potential of the Novel PDE4 Inhibitor Roflumilast in Vitro
inferredcites →https://doi.org/10.1016/s1359-6446(04)03316-1openalex-snapshot
Target-based drug discovery: is something wrong?
inferredcites →https://doi.org/10.1016/s1359-6446(05)03415-xopenalex-snapshot
Finding the target after screening the phenotype
inferredcites →https://doi.org/10.1016/s1359-6446(05)03670-6openalex-snapshot
Finding new drug targets in the 21st century
inferredcites →https://doi.org/10.1016/s1741-8364(04)02394-7openalex-snapshot
Drug discovery information integration: virtual humans for pharmacokinetics
inferredcites →https://doi.org/10.1021/jm00013a022openalex-snapshot
Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer
inferredcites →https://doi.org/10.1021/jm00045a005openalex-snapshot
Synthesis and Quantitative Structure-Activity Relationships of Anticonvulsant 2,3,6-Triaminopyridines
inferredcites →https://doi.org/10.1021/jm000494aopenalex-snapshot
A Novel Series of Highly Potent Benzimidazole-Based Microsomal Triglyceride Transfer Protein Inhibitors
inferredcites →https://doi.org/10.1021/jm00081a011openalex-snapshot
3-Carboxy-5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide, new prodrug for the antiarthritic agent 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide
inferredcites →https://doi.org/10.1021/jm058225dopenalex-snapshot
Designed Multiple Ligands. An Emerging Drug Discovery Paradigm
inferredcites →https://doi.org/10.1021/jm0603015openalex-snapshot
The Physicochemical Challenges of Designing Multiple Ligands
inferredcites →https://doi.org/10.1021/jm060325bopenalex-snapshot
Discovery of (1 R ,5 S )- N -[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2( S )-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2( S )-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3…
inferredcites →https://doi.org/10.1021/jm200108topenalex-snapshot
Discovery and Characterization of Small Molecule Inhibitors of the BET Family Bromodomains
inferredcites →https://doi.org/10.1021/jm201649sopenalex-snapshot
Modern Phenotypic Drug Discovery Is a Viable, Neoclassic Pharma Strategy
inferredcites →https://doi.org/10.1021/jm301268uopenalex-snapshot
Discovery of 2-(2-Oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl)benzonitrile (Perampanel): A Novel, Noncompetitive α-Amino-3-hydroxy-5-methyl-4-isoxazolepropanoic Acid (AMPA) Receptor Antagonist
inferredcites →https://doi.org/10.1021/jm901132vopenalex-snapshot
Selectively Nonselective Kinase Inhibition: Striking the Right Balance
inferredcites →https://doi.org/10.1021/ml400160aopenalex-snapshot
Discovery of Novel Insulin-Like Growth Factor-1 Receptor Inhibitors with Unique Time-Dependent Binding Kinetics
inferredcites →https://doi.org/10.1038/372739a0openalex-snapshot
A protein kinase involved in the regulation of inflammatory cytokine biosynthesis
inferredcites →https://doi.org/10.1038/nature08506openalex-snapshot
Predicting new molecular targets for known drugs
inferredcites →https://doi.org/10.1038/nature12441openalex-snapshot
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers
inferredcites →https://doi.org/10.1038/nbt1228openalex-snapshot
Global mapping of pharmacological space
inferredcites →https://doi.org/10.1038/nchembio.118openalex-snapshot
Network pharmacology: the next paradigm in drug discovery
inferredcites →https://doi.org/10.1038/nchembio.1199openalex-snapshot
Target identification and mechanism of action in chemical biology and drug discovery
inferredcites →https://doi.org/10.1038/nrd2082openalex-snapshot
Drug–target residence time and its implications for lead optimization
inferredcites →https://doi.org/10.1038/nrd2130openalex-snapshot
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
inferredcites →https://doi.org/10.1038/nrd3078openalex-snapshot
How to improve R&D productivity: the pharmaceutical industry's grand challenge
inferredcites →https://doi.org/10.1038/nrd3405openalex-snapshot
The productivity crisis in pharmaceutical R&D
inferredcites →https://doi.org/10.1038/nrd3681openalex-snapshot
Diagnosing the decline in pharmaceutical R&D efficiency
inferredcites →https://doi.org/10.1038/nrd3847openalex-snapshot
Vemurafenib: the first drug approved for BRAF-mutant cancer
inferredcites →https://doi.org/10.1038/nrd4052openalex-snapshot
Emerging paradigms in GPCR allostery: implications for drug discovery
inferredcites →https://doi.org/10.1038/nrd4128openalex-snapshot
Chemical predictive modelling to improve compound quality
inferredcites →https://doi.org/10.1039/b905821bopenalex-snapshot
The topology of drug–target interaction networks: implicit dependence on drug properties and target families
inferredcites →https://doi.org/10.1039/c2md00270aopenalex-snapshot
Investigation of the effect of molecular properties on the binding kinetics of a ligand to its biological target
inferredcites →https://doi.org/10.1039/c3mb25471bopenalex-snapshot
A comprehensive analysis of the influence of drug binding kinetics on drug action at molecular and systems levels
inferredcites →https://doi.org/10.1073/pnas.0502860102openalex-snapshot
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
inferredcites →https://doi.org/10.1073/pnas.0904709106openalex-snapshot
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
inferredcites →https://doi.org/10.1111/j.1476-5381.1991.tb12248.xopenalex-snapshot
Hoe 140 a new potent and long acting bradykinin‐antagonist:in vitrostudies
inferredcites →https://doi.org/10.1111/j.1476-5381.1991.tb12249.xopenalex-snapshot
Hoe 140 a new potent and long acting bradykinin‐antagonist:in vivostudies
inferredcites →https://doi.org/10.1124/jpet.112.197756openalex-snapshot
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker
inferredcites →https://doi.org/10.1124/mol.104.008565openalex-snapshot
The CCR5 Receptor-Based Mechanism of Action of 873140, a Potent Allosteric Noncompetitive HIV Entry Inhibitor
inferredcites →https://doi.org/10.1124/mol.110.069120openalex-snapshot
THRX-198321 Is a Bifunctional Muscarinic Receptor Antagonist and β2-Adrenoceptor Agonist (MABA) That Binds in a Bimodal and Multivalent Manner
inferredcites →https://doi.org/10.1126/science.1106753openalex-snapshot
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
inferredcites →https://doi.org/10.1126/scitranslmed.3001318openalex-snapshot
Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data
inferredcites →https://doi.org/10.1146/annurev-pharmtox-010611-134630openalex-snapshot
Novel Computational Approaches to Polypharmacology as a Means to Define Responses to Individual Drugs
inferredcites →https://doi.org/10.1158/1535-7163.mct-11-0264openalex-snapshot
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
inferredcites →https://doi.org/10.1182/blood-2004-10-4117openalex-snapshot
PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC
inferredcites →https://doi.org/10.1182/blood-2009-04-214957openalex-snapshot
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
inferredcites →https://doi.org/10.1211/0022357001774994openalex-snapshot
Comparative Pharmacodynamics and Pharmacokinetics of Candesartan and Losartan in Man
inferredcites →https://doi.org/10.1248/cpb.58.533openalex-snapshot
Synthesis and Evaluation of Novel Phenylethanolamine Derivatives containing Acetanilides as Potent and Selective .BETA.3-Adrenergic Receptor Agonists
inferredcites →https://doi.org/10.1517/13543776.18.6.603openalex-snapshot
Putative allosteric MEK1 and MEK2 inhibitors
inferredcites →https://doi.org/10.1517/17460441.1.2.99openalex-snapshot
Why has R&D productivity declined in the pharmaceutical industry?
inferredcites →https://doi.org/10.1517/17460441.2011.608658openalex-snapshot
Monitoring Gq-coupled receptor response through inositol phosphate quantification with the IP-One assay
inferredcites →https://doi.org/10.2147/dddt.s19045openalex-snapshot
Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
inferredcites →https://doi.org/10.2174/0929867311320130002openalex-snapshot
Human Disease and Drug Pharmacology, Complex as Real Life
inferredcites →https://doi.org/10.2174/138161209787315594openalex-snapshot
Designing Multiple Ligands – Medicinal Chemistry Strategies and Challenges
inferredcites →https://doi.org/10.2174/156802606776743093openalex-snapshot
Biochemical Mechanisms of New Molecular Entities (NMEs) Approved by United States FDA During 2001-2004: Mechanisms Leading to Optimal Efficacy and Safety
inferredcites →https://doi.org/10.4155/fmc.11.62openalex-snapshot
Computational Tools for Polypharmacology and Repurposing
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.1002/cmdc.201500133openalex-snapshot
Medicinal Chemists of the 21st Century—Who Are We and Where to Go?
inferred← citeshttps://doi.org/10.1002/slct.202201233openalex-snapshot
Design, Synthesis and Anticonvulsant Activity of New Phenoxyalkyl, Phenoxyethoxyethyl and Phenoxyacetyl Derivatives of Aminoalkanols
inferred← citeshttps://doi.org/10.1007/s11030-016-9692-9openalex-snapshot
Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files
inferred← citeshttps://doi.org/10.1016/b978-0-12-409547-2.12318-2openalex-snapshot
Kinetics, Thermodynamics, and Ligand Efficiency Metrics in Drug Discovery
inferred← citeshttps://doi.org/10.1016/j.bmcl.2020.127325openalex-snapshot
Anticonvulsant and analgesic in neuropathic pain activity in a group of new aminoalkanol derivatives
inferred← citeshttps://doi.org/10.1016/j.canlet.2015.02.029openalex-snapshot
Disruption of the unfolded protein response (UPR) by lead compound selectively suppresses cancer cell growth
inferred← citeshttps://doi.org/10.1016/j.drudis.2015.09.009openalex-snapshot
Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective
inferred← citeshttps://doi.org/10.1016/j.molstruc.2024.139431openalex-snapshot
Synthesis of new pyrazine-pyrazole-thiazolidin-4-one and pyrazine-triazole-thiazolidin-4-one conjugates, molecular modelling and docking as antimicrobial agents
inferred← citeshttps://doi.org/10.1038/s41598-019-44025-5openalex-snapshot
Probe dependency in the determination of ligand binding kinetics at a prototypical G protein-coupled receptor
inferred← citeshttps://doi.org/10.1080/17460441.2016.1227317openalex-snapshot
The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors
inferred← citeshttps://doi.org/10.1111/ajt.13582openalex-snapshot
Developing New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward
inferred← citeshttps://doi.org/10.1517/17460441.2015.1043885openalex-snapshot
In silicotools used for compound selection during target-based drug discovery and development
inferred← citeshttps://doi.org/10.3389/fmed.2016.00075openalex-snapshot
The European Lead Factory: A Blueprint for Public–Private Partnerships in Early Drug Discovery
inferred← citeshttps://doi.org/10.3762/bjoc.18.141openalex-snapshot
On drug discovery against infectious diseases and academic medicinal chemistry contributions
inferred← citeshttps://doi.org/10.4155/fmc-2015-0006openalex-snapshot
Polypharmacology: In Silico Methods of Ligand Design and Development
inferred← citeshttps://doi.org/10.4155/fmc-2018-0018openalex-snapshot
Rational Application of Drug Promiscuity in Medicinal Chemistry
inferred← citeshttps://doi.org/10.4155/fmc.15.167openalex-snapshot
One Size Does Not Fit All: Challenging Some Dogmas and Taboos in Drug Discovery
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.